RxDoctor Payments Data

Bernadette Momoh

Psychiatric/Mental Health · Newark, DENPI 1841400223

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 52 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Johnson & Johnson at 28.9% of the total. 2025 is the largest year on record at $1,700, more than ten times the $71 reported in 2021.

$2,752in general payments, 2019–2025

Across 52 payments — averaging $52.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$797
  • Neurocrine Biosciences, Inc.$365
  • AbbVie$342
  • Otsuka America Pharmaceutical, Inc.$339
  • Axsome Therapeutics, Inc.$245
  • Alkermes, Inc.$182
  • plus $483 from 4 others

What the payments were for

  • Food & beverage$2,752100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,752 in reported general payments places this provider in the 80th percentile of 177 psychiatric/mental health providers in Delaware.

See all psychiatric/mental health providers in Delaware

Medicare billing

Part B allowed, 2024
$21,672
Medicare patients
68
Services billed
249

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl12$20,205
Lurasidone Hcl49$16,239
Aripiprazole43$3,287
Lacosamide11$2,949
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl11$2,266
Bupropion XlBupropion Hcl65$1,918
Venlafaxine Hcl ErVenlafaxine Hcl30$826
Quetiapine Fumarate43$788
Duloxetine Hcl17$744
Mirtazapine32$568
Escitalopram Oxalate32$559
Buspirone Hcl52$537
Olanzapine19$413
Guanfacine Hcl ErGuanfacine Hcl11$367
Fluoxetine Hcl44$338

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$342$20,20512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 177 psychiatric/mental health providers in Delaware.

Other psychiatric/mental health in Newark

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →